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ABSTRACT
A recombinant plasmid containing human interleukin 2 (IL2) cDNA was
identified in a cDNA library constructed from mRNA derived from PHA-TPA
induced splenocytes. Using this cDNA as a hybridization probe, a DNA
fragment containing the IL2 gene was isolated from a collection of hybrid
phages derived from human genomic DNA. A unique reading frame was
identified from the nucleotide sequence derived from these plasmids coding
for a polypeptide of 153 amino acids and containing a putative signal
sequence of 20 amino acids. A mature polypeptide starting with either
Met-Ala-Pro or Met-Pro was expressed in E. coli under control of the E.
coli trp promoter or using a combination of the phage A PL promoter and a
ribosome binding site derived from phage Mu. The bacterial IL2
polypeptide had a molecular weight of 15,000 daltons and accounted for
more than 10% of the total E. coli proteins in fully induced cells; it was
biologically active in the T-cell specific DNA synthesis assay, even after
recovery from a SDS-containing polyacrylamide gel.
INTRODUCTION
Human interleukin 2 (IL2 or T-cell growth factor) is defined as a
protein whose activity allows the long-term proliferation of T-cells
following interaction with antigen (1-3). It is an inducible protein
synthesized and secreted by activated T-lymphocytes (4) and has been
purified from various sources such as human peripheral blood lymphocytes
(3,5,6), tonsilar lymphocytes (7), spleen lymphocytes (8), T-cell leukemia
(9,10) and T-cell hybridoma cultures (11,12). The molecular weight
reported for the SDS-denatured human IL2 ranges from 12000 to 17000
(3,11,13). It is believed that this molecular heterogeneity is dependent
on the experimental conditions for the IL2 production (13) and may be
explained perhaps by a variable degree of glycosylation (7,14). On the
other hand, the finding that IL2 does not bind on a lectin column (3)
would seem to indicate that the protein is unglycosylated. Recently,
IL2-mRNA isolated from mouse (15), primate (16), human tonsilar (17) and
peripheral blood lymphocytes (18) has been translated in Xenopus laevis
oocytes, while IL2-mRNA, isolated from a human T-cell line was efficiently
translated in a reticulocyte lysate (11). Monoclonal antibodies binding
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human IL2 (19,20) and monoclonal antibodies specific for the human IL2
membrane receptor (21) have been prepared. Human IL2 preparations are
active on human, rat and mouse IL2-dependent cells (22). IL2 augments NK
cell-mediated cytotoxicity in addition to its activation by interferon
(23). IL2 has been used extensively for cloning various T-cell subsets
(24) and NK cells (25) suggesting a potential use for specific adaptive
immunotherapy of neoplasia by systemic transfer of expanded lymphoid cells
(26,27). Deficiency in IL2 production has been shown to occur in certain
diseases characterized by immunodeficiencies (28,29) supporting its
essential role for the full expression of the human immune response.
In this report, we describe the characterization of a human IL2 cDNA
gene and its expression in E. coli. The method we have used for cloning
the IL2 cDNA was essentially identical to the strategy used for cloning
the human immune interferon (IFN-6 ) cDNA gene (30). Recently, the human
IL2 cDNA gene, derived from a T-cell leukemia was cloned and expressed in
eukaryotic cells (31). The availability of an IL2 cDNA-containing plasmid
will allow for the large scale production and purification of human IL2
derived from genetically engineered cells. We also report the isolation
and characterization of the human genomic IL2 gene.
MATERIALS AND METHODS
1. Biological assay for interleukin 2
Mononuclear cells were isolated from human peripheral blood by means of
'lymphoprep' (Neygaard & Co.). The cells at the interphase were washed
twice and cultured at a concentration of 5 x 105 cells/ml in RPMI 1640
medium , supplemented with 1% L-glutamine, antibiotics and 10% fetal calf
serum. The cells were stimulated with phytohemagglutinin (PHA) lO.g/ml
(Wellcome) for 20 h at 370C. The cells were then collected, intensively
washed and cultured for another 3 days in medium without PHA. On the
fourth day, the cells were supplemented with 5% of a partially purified
human IL2 preparation [a 50%-80% (NH+ SO4 precipitate derived from the
medium of PHA stimulated splenocytes, redissolved in 1/20 of the original
volume, exhaustively dialyzed against phosphate buffered saline (2)].
Every 3 to 4 days, the cells were split at a ratio of 1/2. Living cells
from cultures, approximately 2 to 3 weeks old were washed and concentrated
in IL2-free medium with 40% fetal calf serum and 10% dimethylsulfoxide to
give a final concentration of 2 x IO cells/ml. Immediately thereafter,
cells were frozen in 1 ml glass vials, using a controlled-rate freezer
(CRYOSON), applying cooling rates of 10C/min to -450C and then quickly to
-80"C. The target cells were then stored in liquid nitrogen (33).
Immediately before use, the cells were thawed rapidly at 37 C, mixed
stepwise with medium and washed. Viability was examined by Trypan blue
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exclusion.
The IL2 microassay was performed according to Gillis et al. (4).
100,j.l IL2 samples were serially diluted (1/2) in 96-well microtiter
plates (Falcon) (in RPMI 1640, 10% fetal calf serum, 1% L-glutamine and
antibiotics). The target cells were suspended at 2 x 105 cells/ml and
100lAl was supplied to the wells. Microtiter plates were incubated at 37 C
for 24 h in a humidified atmosphere of 5% CO, in air. Next, 0.5pACi of
3H-labelled thymidine (Amersham 20-30 Ci/mmole) was added to each
microDlate well and cultured for an additional 5 h. Cultures were
harvested onto glass filter strips (with a cell-harvester; type MASH
II). 3H-Thymidine incorporation was determined with a liquid
scintillation counter.
The standard (an arbitrarily chosen human IL2 containing supernatant)
was defined as containing 100 U/ml and induced maximal proliferation up to
dilutions of 1/4 to 1/8 as measured by 3H-thymidine uptake. 30% of the
maximal activity of this sample was usually located in the centre of the
linear descending part of the standard curve. Each test sample was also
tested at serial dilutions and the titre was calculated by a graphical
regression analysis. The activity in each test sample was converted into
units according to Stadler et al. (20).
2. Construction and screening of cDNA plasmids
Human splenocytes from an individual donor were isolated (37) and cultured
for 20 h at 37 C in the presence of PHA (10 ,u-gml') and TPA (10 ngml').
Total RNA was extracted (34) from the washed splenocytes and
polyadenylated RNA isolated by oligo dT-cellulose chromatography (Type
3-Collaborative Research). 0.5 mg polyadenylated RNA was fractionated on
a 5-20% sucrose gradient in TE-buffer (1OmM Tris HCI, pH 7.5, lmM EDTA)
(16 h, 40K, Beckman SW41 rotor, 40C). Fractions were precipitated with
ethanol, dissolved in 30j1l distilled H;O and assayed for IL2 mRNA
activity by microinjection of 30 nl into X. laevis oocytes. After 3 days
at 230C, 1001t1 of the oocyte bathing medium (containing 0.1% polyethylene
glycol 6000 and 0.4% Aprotinin, Sigma) was used for measuring the
3H-thymidine incorporation by PHA stimulated IL2 dependent human PBLs
(4,20,33). ds DNA was synthesized (38) using 20 mg polyA*RNA from
fractions for which IL2 activity was observed (3 fractions). The dsDNA
between 600 and 750 bo (M3) and between 750 and 1000 bp (M2) was recovered
from a 4% polyacrylamide gel, purified on hydroxyapatite and tailed with
oligo dG using terminal deoxynucleotidyl transferase (PL Biochemicals).
Next, the dsDNA was annealed with pSV529 DNA (39) of which the sticky ends
resulting from Bam HI cleavage were filled in with AMV reverse transcriptase
and further extended with dC residues. The annealed mixture was used to
transform E. coli HBIOI and resulting colonies derived from each dsDNA
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size class (M2 and M3) were picked up and grown individually in wells of
microtiter plates. Plasmid DNA was isolated (41) from overnight cultures
(0.5 liter Brain Heart Infusion containing lOO1ug ml ' carbenicillin) each
consisting of a mixture of 50 individual clones, purified by CsCl gradient
centrifugation, cleaved with Bam HI followed by sucrose gradient
centrifugation. The optical density peak corresponding to "insert-DNA"
(30) (5 to 10,ug) was ethanol precipitated, dissolved in TE-buffer and
immobilized onto nitrocellulose filters (42) (Schleicher & Schull BA85,
0.45#um, 9mma squares). A total of 30 filters (18 derived from group M2
and 12 derived from M3) were prehybridized for 2 h at 50½C in 0.5 ml
hybridization mixture (40) without RNA and hybridized for 5 h at 500C in
an identical mixture in the presence of 50/hg polyA+RNA isolated from
PHA-TPA induced splenocytes, purified on a sucrose gradient and previously
assayed for IL2 mRNA activity. RNA eluted from washed filters (40) was
assayed for IL2 mRNA activity by microinjection into X. laevis oocytes as
described above.
3. Induction of HIL2 in E. coli and SDS-PAG electrophoresis of E. coli
extracts
Conditions for induced synthesis of HIL2 by plasmids in strain K-126HIhtrp
were as described by Remaut et al. (46) with minor modifications.
Induction of the trp promoter was obtained after tryptophan starvation of
E. coli strain K514 growing in M9 medium (47). Cells were collected by
centrifugation, dissolved in Laemli sample buffer (48) and electrophoresed
in 15% polyacrylamide gels . Alternatively, cells were opened by
sonication and after centrifugation, the sunernatant and the cell pellet
was taken up in Laemli sample buffer and electrophoresed as above.
4. Identification of genomic clones containing HIL2 DNA in human DNA
libraries
The methods used in the identification were as described by Tavernier et
al. (49).
RESULTS AND DISCUSSION
1. Isolation of IL2 mRNA from PHA-TPA induced human §plenocytes
Human splenocytes (30) were stimulated with phytohemaglutinin (PHA) and a
phorbol ester (TPA) (32) for 20 h at 37TC after which time the IL2 in the
medium was assayed by measuring the proliferation of PHA-stimulated IL2-
dependent human peripheral blood lymphocytes (PBLs) (4,20,33), and
polyadenylated RNA was isolated from the collected cells (34). Further
enrichment of IL2-specific mRNA was obtained by sucrose gradient
centrifugation under non-denaturing conditions (35). IL2 mRNA was
identified by microinjection of sucrose gradient derived fractions into
Xenopus laevis oocytes (36) and the incubation medium was assayed (37) for
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IL2 activity. A reproducible activity corresponding to mRNA which
sedimented at lOS was observed for most of the individual splenocyte
cultures (data not shown). This is in agreement with the sedimentation
values reported for IL2 mRNA derived from human PBLs (18) and from human
tonsilar lymphocytes (17). Kinetic studies showed that this IL2 activity
still accumulated into the medium of microinjected oocytes after 3 days of
incubation.
2. Contruction and identification of bacterial clones containing IL2-cDNA
sequences
dsDNA was synthesized on polyAt RNA (from a single donor) using standard
procedures (38), fractionated by polyacrylamide gel electrophoresis and
appropriate size classes, ranging in length from 600 to 750 bp (group M3)
and 750 to 1000 bp (group M2) were tailed with oligo dG and inserted into
the unique Bam HI site (filled in with AMV reverse transcriptase and
tailed with oligo dC) of plasmid pSV529 (39) and used for transformation
of E. coli HBll. Since the Bam HI site of the vector pSV529 was restored
by the cloning procedure, "insert-DNA" was prepared by Bam HI-digestion of
plasmid DNA isolated from mixtures of 50 clones. The "insert-DNA" was
then purified by gradient centrifugation and bound onto nitrocellulose.
Hybridization of 30 filters (18 filters of group M2 and 12 filters of
group M3) with PolyA RNA derived from PHA-TPA induced splenocytes (and
purified on a sucrose gradient) and subsequent elution (40),
microinjection into Xenopus laevis oocytes and assay of the oocyte medium
for IL2 activity yielded 2 filters, M3-2 and M3-6, which gave a clear
positive signal (Table I). Subsequent hybridization of filters containing
"insert-DNA" derived from 14 different subgroups (each containing 7
clones) from the group M3-2 with IL2-mRNA, led to the identification of
the IL2-cDNA-containing plasmid (M3-2-32, Fig lA). This was confirmed by
hybridizing a filter containing only "insert-DNA" isolated from clone
M3-2-32 with IL2-mRNA (Fig lB). This first positive clone was renamed
pSV-HIL2-0. Gel electrophoresis revealed that the Bam HI excised
"insert-DNA" was approximately 750 bp in length. Colony hybridization
(43,44) of 1300 colonies from group M2 and 1050 from group M3 with a
5;P-labelled (45) internal Hinf fragment (500 bp) derived from pSV-HIL2-0
resulted in the identification of one additional clone (M3-6-41,
designated pSV-HIL2-l) in the group M3. This second clone is derived from
group M3-6 which gave a positive signal in the first hybridization-elution
translation screening assay (Table I). The Bam HI excised "insert-DNA",
derived from the pSV-HIL2 plasmid preparations was purified by sucrose
gradient centrifugation and mapped using restriction enzymes. Further
characterization of these insert-DNAs revealed that the insert present in
pSV-HIL2-l was only 250 bp in length and corresponded to an internal
sequence within "insert-DNA" derived from pSV-HIL2-0. Such a small insert
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TABLE I
Identification of a human IL2 cDNA containing plasmid in a group of
50 individual bacterial clones
Filter No. Group cpm* Filter No. Group cpm*
1 M2-1 569 16 M2-16 338
2 2 533 17 17 302
3 3 386 18 18 357
4 4 305 19 M3- 1 248
5 5 293 20 2 7238
6 6 410 21 3 322
7 7 254 22 4 329
8 8 333 23 5 366
9 9 297 24 6 1719
10 10 235 25 7 345
11 11 253 26 8 311
12 12 297 27 9 397
13 13 411 28 10 387
14 14 263 29 11 310
15 15 428 30 12 373
Cl 11654
C2 3861
blank 314
standard 20576
Cl: (Control 1) injection into Xenopus laevis oocytes of polyA RNA
before use in the hybridization-elution assay.
C2: (Control 2) injection into Xenopus laevis oocytes of polyA RNA after
hybridization with the nitrocellulose filters
(non-hybridized RNA).
blank: 100al complete medium (RPMI 1640 + 10% FCS) used in the IL2 assay.
standard: partially purified human IL2 preparation from PHA/TPA induced
3 splenocyte cultures.
cpm: H-thymidine incorporation of 1/4 dilution of oocyte incubation
medium by PHA-stimulated IL2 dependent human peripheral
blood lymphocytes.
DNA probably originated through internal dG-tailing at a nick present in
the sized ds-cDNA.
3. Nucleotide sequence of the human IL2-cDNA gene and deduced amino acid
sequence
a.Characterization of the "insert-DNA" derived from pSV-HIL2-0
Fig. 2 shows a physical map of the IL2 gene together with the sequencing
strategy and the restriction map. The nucleotide sequence of the insert
derived from plasmid pSV-HIL2-0 and completed with sequence information
from the genomic clone is shown in Fig. 3. A nucleotide sequence typical
for the 3' end of a eukaryotic mRNA containing the potential
polyadenylation signal AAUAAA was identified. Although an ATG start codon
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Fig. 1 Screening for a human IL2 cDNA-containing clone in subgroups of
M3-2 (A) and identification of an individual clone (B).
A. Plasmid DNA was isolated from 0.5 liter cultures, each containing a
combination of 7 individual clones (group A to M, except group N which
contained 8 clones, see insert). The DNA was cleaved with Bam HI and the
excised "insert-DNA" purified by sucrose gradient centrifugation and
immobilized on nitrocellulose filters. Next the filters were hybridized
with 80,Mg sucrose gradient purified polyA+RNA derived from PHA-TPA
induced splenocytes, washed and the eluted RNA injected into X. laevis
oocytes. The oocyte bathing medium, Cl, C2, standard and blank (see
legend to Table I) was used in the IL2 microassay (filters G, H, I and J
were not tested).
B. Hybridization-elution-translation assay of filters containing insert
DNA isolated from group M3-1 (negative control), subgroups D and L and the
individual clone M3-2-32.
and part of its 5'-coding region was missing from the cDNA clone, the
nucleotide sequence of pSV-Hil2-0 shows a unique reading frame of 134
amino acids (Fig.3). No potential N-glycosylation sites could be
identified within this amino acid sequence. To establish the number of
missing nucleotides at the 5'-end of the IL2-cDNA insert, a short (63 bp)
restriction endonuclease fragment (Alu I - Hinf I, nucleotide 36-99 in
pSV-HIL2-0) (see Fig 2) was isolated, 5'-labelled, strand separated and
extended by reverse transcription after hybridization to polyA*RNA derived
from induced splenocytes. Analysis of the cDNA product on a denaturing
polyacrylamide gel showed a band of around 210 nucleotides (Fig.4). From
this result, we can deduce that the insert in pSV-HIL2-0 is approximately
110 nucleotides shorter than the full-length IL2 mRNA (210 minus 99
nucleotides).
b. The nucleotide sequence of the 5'-end of the human IL2 cDNA gene.
isolation of a genomic IL2 gene
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Fig. 2. Restriction map and sequencing strategy for the human IL2 gene.
The diagram shows a schematic representation of part of the putative
promoter (black box at left), followed by the transcribed region
consisting of the 5' untranslated segment (line), the signal sequence (SS
bar), the coding region (open bar) and the 3' untranslated sequence(line). The cDNA clone, which started at the second last codon of the
signal sequence, is indicated; the wavy line refers to the G/C-tails. The
sequence upstream from the cDNA information was derived from a genomic
clone. Some restriction sites are indicated on top; all were
experimentally verified. Below, the sequencing strategy by the 2
Maxam-Gilbert procedure (55) is given. Open squares correspond to 3a-
labeled 5'-ends and open circles indicate 3'-end labeling.
original cDNA clone, we isolated a genomic clone containing the IL2 gene
from a human DNA library. Southern hybridization (50) of high molecular
weight human DNA, digested with various restriction endonucleases, with
.32P-labelled IL2 cDNA suggested that there is only one IL2 gene in the
human genome (data not shown). Two human gene banks (51, 52) plated on E.
coli BHB 2600 were screened in situ (53) using a 32P-labelled IL2-cDNA
specific Hinf fragment derived from PAT153-HIL2 (see next section). A
total of 5 hybridization-positive phage plaques were isolated from the two
banks. One of these (;kCH4A-gHil2-l) was shown to contain the total human
IL2-gene and was analysed in further detail. The total IL2 gene was then
subcloned in pUR250 (54) as two Eco RI restriction endonuclease fragments
(pUR-gHil2-1 and pUR-gHil2-2). pUR-gHil2-1 was shown both by restriction
analysis and hybridization data to contain the promoter region and the
5'-part of the transcribed human IL2 gene. Detailed restriction analysis
of both subclones gave evidence for the presence of at least two introns
in the coding region (data to be reported elsewhere). Fig. 3 also shows
the nucleotide sequence of the 5'-end of the IL2 gene as deduced from
pUR-gHi12-l. The presence of an ATG initiation codon, approximately 60
nucleotides in front of the nucleotide sequence overlapping our original
cDNA clone, resulted in a total coding sequence of 153 amino acids. Since
the IL2 mRNA is approximately 110 nucleotides longer than the cDNA clone,
4314
Nucleic Acids Research
CCCCATAATA TTTTTCCAGA ATTAACAGTA TAAATTGCAT CTCTTGTTCA AGAGTTCCCT
* MET TYR ARG MET GLN LEU
AUCACC UCUULAAUCA CUACUCACAG ULACCUAA LUCCUGCCACAAUG UAC AGG AmG CAA CUC
50
20 1
LEU SER CYS ILE ALA LEU SER LEU ALA LEU VAL THR ASN SER ALA PRO THR SER SER
CmG UCU UGC AW GCA CUA AGU CUU GCA CUU GIC ACA AAC AGU GCA CCU ACU UCA AIGU
100
20
SER THR LYS LYS THR GLN LEU GLN LEU GLU HIS LEU LEU LEU ASP LEU GLN MET ILE
CU ACA AAG AA A CAG CIA CAA CmG GAG CAU UUA CUG CUG GAU UUA CAG AUG AW
150
LO
LEU-ASN GLY ILE ASN ASN TYR LYS ASN PRO LYS LEU THR ARG MET LEU THR PHE LYS
mG AAU GGA AW AAU AAU UAC AAG AAU CCC AAA CLC ACC AGG AmJG CLC AA UUU AAG
20D 60
PHE TYR MET PRO LYS LYS ALA THR GLU LEU LYS HIS LEU GLN CYS LEU GLU GLU GLU
UUU UAC AUG CCC AAG AAG GCC ACA GM CUG MA CAU CUU CAG UGU CA GM GM GM
250 80
LEU LYS PRO LEU GLU GLU VAL LEU ASN LEU ALA GLN SER LYS ASN PHE HIS LEU ARG
CLC AAA CCU CmG GAG GAA GUG CUA AAU UUA GCU CAA AGC AAA AAC UiUCKuc A AGA
300 350
100
PRO ARG ASP LEU ILE SER ASN ILE ASN VAL ILE VAL LEU GLU LEU LYS GLY SER GLU
CCC AGG GAC UUA ALC AGC MU ALC AAC GUA ALIA GUU CmG GAA CUA AAG GGA UCU GAA
400
THR THR PHE MET CYS GLU TYR ALA ASP GLU THR ALA THR ILE VAL GLU PHE LEU ASN
ACA A LC AmG UGU GAA UAU GCU GAU GAG ACA GCA ACC AUU GUA GM UUU CUG AC
450
120
ARG TRP ILE THR PHE CYS GLN SER ILE ILE SER THR LEU THR
AGA UGG AUU ACC UUU mGU CAA AGC AlC AlC lUA ACA CmG ACUUGAUAAuUmGUG cult
500
CCACW AAAACALIAL AGGCCUUCUA UULUUUAMA UAUUUAAAUU LIAUAUUUAU UGUUGAAmGU AU
550
GGWUUGCU ACCUAUUGUA ACUUAUUUC ULAAUCUUAA AACUAAAAU AUGGALCUUU LAUGAUICUU
600
UUUJGUAAGCC CLUAG Clt LAAUGGUU lCACULIAUW ALCCCAAAAU AUUlUAUUAUU ALULM
700
mG ULAMIALWG IAUCUAmGiLA GAUUGGUUL UIAAAUIUU ULAAAAUUU GAUAA
750
Fig. 3 Nucleotide sequence and deduced amino acid sequence of the human
interleukin 2 gene. Data derived from the genomic clone (pUR-gHil2-1) is
underlined and the sequence, preceding the start of the IL2 mRNA and
corresponding to part of the putative promotor, is shown (as DNA) in
italics. A TATAAAT-consensus sequence (overriding bar) is present 32
nucleotides upstream from the putative first nucleotide (indicated by an
asterisk) of the IL2 mRNA. (This tentative identification of the first
nucleotide of the transcript is based on the results of Taniguchi et al.
(31) who obtained a full size cDNA clone, and is in agreement with our
mRNA mapping data shown in Fig. 4.) The arrow indicates the presumed
signal sequence cleavage site (based on the known N-terminal amino acid
sequence of natural human IL2). The poly-A signal, AAUAAA, is
underlined. The numbers above each line refer to amino acid positions,
while those below, to nucleotide positions. Note that the second to last
codon, CUG for leucine, was a CUA in the sequence of Taniguchi et al.
(31), which indicates a silent substitution at position 503.
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pSV-HIL2-0, the presence of this ATG codon results in a 5' non-coding
region of approximately 50 nucleotides. We have renumbered our nucleotide
sequence on the basis of the results obtained on a presumably complete
human IL2 cDNA clone reported recently by Taniguchi et al. (31). Indeed,
our sequence data revealed the presence of a TATAAAT-concensus segment,
typical for a eukaryotic promoter at position -32 nucleotides as
expected. A putative signal peptide sequence of 20 amino acids can be
identified (Fig. 3), cleavage of which results in a mature polypeptide of
133 amino acids having a molecular weight of 15,400. The amino acid
sequence shows an almost identical number of basic and acidic residues,
explaining the neutral pI value observed for the natural human IL2 (3).
The polypeptide sequence contains three cysteine residues, two of which
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might be involved in an intramolecular disulfide bridge.
The nucleotide sequence we have determined for the IL2 mRNA and amino
acid sequence deduced for IL2 is in complete agreement with the data
obtained by Taniguchi et al. except for the nucleotide at position 503
which we determined to be G as opposed to A. This substitution does not
lead to a change in the amino acid sequence. It should be noted that our
clone was derived from normal splenocytes while the one of Taniguchi et
al. (31) was derived from the human Jurkat 111 cell line. Also, our
assays were done on human PBL while Taniguchi et al. used the mouse cell
line CTLL-2. The lack of a potential N-glycosylation site explains why
IL2 is not retained on lectin columns (3). The change in heterogeneity of
the pI value after treatment with neuraminidase (14) and the observed
heterogeneity in molecular weight distribution after induction of IL2 by
different stimuli (13) remains to be explained.
4. Expression of human IL2 in E. coli
a. Construction of plasmids
Mature IL2 starts with an alanine residue. From the nucleotide
sequence it can be seen that the second amino acid residue (Pro) can be
easily exposed after HgiAl cleavage and resection of the 3' protruding end
with T+ DNA polymerase. To add an alanine codon to the 5'-end, the
following successive cloning steps were carried out (Fig. 5). The Bam HI
insert, derived from pSV-Hil2-0, containing the mature IL2 coding region
was inserted into pAT153. The new plasmid, pATI53-Hil2, was cleaved with
HgiAl, treated with T4 polymerase and, after cleavage with Bam HI, the
resulting 700 bp fragment was ligated between a Bam HI site and a
filled-in Nar I site of pAT153. The reconstructed Nar I site (GGCGCC) is
also a Ban I site (isochisomer of HgiCI). The enzyme Ban I cleaves the
recognition sequence between the two G residues leaving 5' protruding ends
(G4'GCGCC). Following filling-in, a GCG codon (Ala) is added to the 5' end
of the coding sequence of mature IL2. After Bam HI cleavage, the fragment
was cloned between a filled-in Nco I site and a Bam HI site of the
expression vectors pPLcMu299 and pTrp321 (obtained form G. Buell, Biogen,
S.A.). In these plasmids, the Nco I site is located at the initiator ATG
such that the latter can be made accessible for blunt ligation after Nco I
cleavage and filling-in with DNA polymerase I (Klenow fragment). Plasmid
pPLcMuHIL201, contains the complete coding region for mature IL2 in phase
with the initiator ATG of a ribosome binding site derived from phage Mu.
The sequence at the initiator ATG then is: TTAGGAGGGTTTTTACC ATG.GCG.CCT.
In plasmid pTrpHIL201, the ribosome binding site and initiator ATG derived
from the trp attenuator region were used. The sequence at the initiator
ATG reads: AAAGGGTATCGATTCC ATG.GCG.CCT. Both plasmids were shown to
indeed contain a unique Nco I site as predicted by joining the GCG codon
to the blunted Nco I site of the acceptor plasmids.
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We have also constructed plasmids in which the Pro residue is directly
joined to the initiator ATG of both pPLcMu299 and pTrp32l. To do this,
the blunted HgiAl site was directly ligated to the filled-in NcoI site of
the expression vectors. The resulting plasmids were designated pMuHIL21
and pTrpHIL21. A further derivative, pPLcMuHIL22 is essentially identical
to pPLcMuHIL21 except that it contains a smaller vector part derived from
pPLc28 (46) .
Expression studies with vectors using the PL promoter were carried out
in strain K12aHlsetrp (47). Threinitiatin grown at28- C and induced at
42°C (46). Induction of the trp promoter was obtained after tryptophan
starvation of strain K514;k(48). To test for biological activity of
bacterially synthesized human IL2, the cells were opened by sonication;
cell debris was spun down and the supernatant was passed through a 0.2,a
Millipore filter. These extracts were then assayed for T-cell growth
activity. From the results shown in Table 2, it can be concluded that
extracts of induced cultures contain IL2 activity, while similar extracts
from uninduced cultures scored negative. Both the protein initiating with
Met-Ala-Pro, as well as the one initiating with Met-Pro, were biologically-
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Table II
Expression of HIL 2 in E. coli
Sample IL2 Units /ml
A. HIL2 starting with Met-Ala-Pro
HIL2 standard 100
+ 25% control bacterial extract 70
"I "I + 2.5% " " 81
pPLcMu-Hil2Ol 28 C 41
"1 42C 850
pTrp-32 1 <1
pTrp-Hil2Ol (induced by tryptophan depletion) 3800
B. HIL2 starting with Met-Pro
pPLcMu-Hil22 28 C <1
"1 42 C 250
pTrp-Hil2l (induced by tryptophan depletion) 2100
10 ml cultures of E. coli K12AHlatrp (containing pPLcMu-Hil2
plasmids) grown at 28*Cnd induced at 42"C or of E. coli K514A
(containing pTrp-Hil2 plasmids) grown at 373 C and induced by depletion of
exogenous tryptophan) were concentrated 10 fold. The cells were lysed by
sonication. The extracts were centrifuged, passed through a 0.2A
Millipore filter and assayed for IL2 activity as described in Materials
and Methods. 1, 10 and 100A-1 of each sample were used at serial
dilutions (1/2) and 3H-thymidine incorporation by PHA-stimulated human
peripheral blood lymphocytes was measured. IL2 was quantified as
described (4,20,33).
active. However, it is not known whether the specific activity of the
product starting with Met-Ala-Pro is different from the specific activity
of the product beginning with Met-Pro.
b. Physical detection of HIL2 and recovery of biologically active
bacterially derived HIL2 from SDS-containing polyacrylamide gels
Total bacterial extracts of E. coli, harboring either plasmid
pPLcMu-Hil2Ol (induced at 42°C) or plasmid pTrp-Hil2Ol (induced by
depletion of exogenous tryptophan) were denatured in SDS and analysed in
SDS-containing polyacrylamide gels(48). As shown in Fig 6, a new protein
having a molecular weight of about 15K can be detected. This protein is
absent in extracts prepared from identical cultures grown at 280C (for
pPLcMu-HIil2Ol) and in extracts prepared from a control culture not
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A. Physical detection of bacterially derived HIL2 in a SDS-polyacrylamide
gel. 280 and 420: electrophoresis of total bacterial extracts containing
plasmid pPLcMu-Hil2Ol grown at 280C and 420C, respectively. - and +:
electrophoresis of total bacterial extracts containing plasmid pTrp321(-)
or plasmid pTrp-Hil2Ol(+). p: electrophoresis of bacterial debris
obtained by centrifugation of a sonicated bacterial culture containing
either plasmid pPLcMu-Hil2Ol (grown at 42 C) or pTrp-Hil2Ol.
B. Recovery of biologically active bacterially derived HIL2 from
SDS-polyacrylamide gel. 28Cand 42- electrophoresis of total bacterial
extracts containing plasmid pPLcMu-Hil2Ol grown at 280C and 420C,
respectively. - or +: electrophoresis of total bacterial extracts
containing plasmid pTrp321 (-) or plasmid pTrp-Hil2Ol(+).
carrying plasmid pTrp-Hil2Ql and grown at 370C. From the intensity of the
stained band, the protein was estimated to have accumulated to about 5%
and 10% of the total cellular protein in the cases of pPLcMu-Hil2Ol and
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pTrp-Hil2Ol, respectively. E. coli harboring plasmids pPLcMu-Hil22 and
pTrp-Hil2l, designed to express IL2 initiating with Met-Pro, also led to
the inducible synthesis of a 15K protein estimated at about 5% and 10% of
total cellular protein, respectively (data not shown). SDS denaturation
and gel electrophoresis of the bacterial debris obtained after clearing
sonicated bacterial extracts by centrifugation showed that most of the
synthesized IL2 remains insoluble (Fig 6.A). The biological activity
found in the cleared extracts (Table 2.A and 2.B), therefore, is not
quantitative and in no relation to the total bacterial synthesis. To
determine whether the biologically active HIL2, present in the bacterial
cleared extracts, corresponds to the inducible protein having a molecular
weight of 15K in SDS-polyacrylamide gels, the total bacterial extracts
were denatured with SDS and A -mercaptoethanol and electrophoresed as for
Fig 6A. The gel was then cut into 2 mm slices and each slice crushed into
0.2 ml RPMI 1640 + 10% FCS medium. Following overnight incubation at 37 C
and centrifugation, the supernatant was removed and the IL2 activity
determined as described above. The results show (Fig 6.B) that the HIL2
biological activity, indeed, comigrates with the strong protein band
present upon induction of cells containing either plasmid pPLcMuHil2Ol or
plasmid pTrpHil201.
Purification of this bacterially expressed IL2 will provide large
amounts of human IL2 needed for studies on cloning and culturing antigen
specific T-cell lines. The availability of pure recombinant derived
lymphokines such as IFN-6 and IL2 will certainly lead towards a better
understanding of the different factors involved in effector cell functions
in the immune system.
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